Princeton Capital Management LLC Acquires Shares of 23,018 Astrazeneca Plc $AZN

Princeton Capital Management LLC acquired a new stake in shares of Astrazeneca Plc (NYSE:AZN) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 23,018 shares of the company’s stock, valued at approximately $4,040,000. Astrazeneca makes up 1.0% of Princeton Capital Management LLC’s investment portfolio, making the stock its 18th largest position.

Several other institutional investors have also added to or reduced their stakes in the company. Luken Investment Analytics LLC raised its position in Astrazeneca by 4.3% during the fourth quarter. Luken Investment Analytics LLC now owns 1,564 shares of the company’s stock valued at $274,000 after purchasing an additional 64 shares in the last quarter. Western Wealth Management LLC increased its holdings in shares of Astrazeneca by 2.5% during the fourth quarter. Western Wealth Management LLC now owns 2,887 shares of the company’s stock worth $507,000 after buying an additional 71 shares in the last quarter. Soltis Investment Advisors LLC increased its holdings in shares of Astrazeneca by 2.2% during the fourth quarter. Soltis Investment Advisors LLC now owns 3,470 shares of the company’s stock worth $609,000 after buying an additional 76 shares in the last quarter. LRI Investments LLC increased its holdings in shares of Astrazeneca by 2.4% during the fourth quarter. LRI Investments LLC now owns 3,358 shares of the company’s stock worth $589,000 after buying an additional 78 shares in the last quarter. Finally, GRIMES & Co WEALTH MANAGEMENT LLC increased its holdings in shares of Astrazeneca by 1.9% during the fourth quarter. GRIMES & Co WEALTH MANAGEMENT LLC now owns 5,336 shares of the company’s stock worth $936,000 after buying an additional 98 shares in the last quarter. 20.35% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

AZN has been the subject of several research analyst reports. JPMorgan Chase & Co. reiterated a “buy” rating on shares of Astrazeneca in a report on Thursday, May 14th. Barclays upgraded Astrazeneca from a “neutral” rating to a “buy” rating in a report on Wednesday, April 29th. Weiss Ratings began coverage on Astrazeneca in a report on Wednesday, March 11th. They issued a “buy (b)” rating for the company. TD Cowen restated a “buy” rating on shares of Astrazeneca in a report on Wednesday, March 18th. Finally, UBS Group restated a “buy” rating on shares of Astrazeneca in a report on Friday, April 10th. Twelve equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $205.33.

Astrazeneca Stock Performance

NYSE AZN opened at $187.50 on Thursday. The company has a market capitalization of $290.79 billion, a price-to-earnings ratio of 28.15, a PEG ratio of 1.52 and a beta of 0.26. Astrazeneca Plc has a twelve month low of $137.23 and a twelve month high of $212.71. The stock has a fifty day simple moving average of $191.82 and a 200 day simple moving average of $182.58. The company has a quick ratio of 0.71, a current ratio of 0.91 and a debt-to-equity ratio of 0.52.

Astrazeneca (NYSE:AZN) last issued its quarterly earnings results on Wednesday, April 29th. The company reported $2.58 EPS for the quarter, beating analysts’ consensus estimates of $2.52 by $0.06. The business had revenue of $15.29 billion for the quarter, compared to analysts’ expectations of $14.93 billion. Astrazeneca had a net margin of 17.19% and a return on equity of 30.86%. Sell-side analysts expect that Astrazeneca Plc will post 10.25 EPS for the current year.

About Astrazeneca

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.